Eris Lifesciences Limited is planning to hit the streets with an IPO which would be open for subscription between June 16, 2017 and June 20, 2017
Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select Therapeutic Areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics)
The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. For the sale of up to 28,875,000 Equity Shares by the Selling Shareholders.
